SEC Comment Letter 0000000000-23-000505 to NewcelX Ltd. (NCEL)
NewcelX Ltd.
Date: Jan. 18, 2023 · CIK: 0001783036 · Accession: 0000000000-23-000505
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269220
Letter
United States securities and exchange commission logo January 18, 2023 Alexander Zwyer Chief Executive Officer NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland Re:NLS Pharmaceutics Ltd. Registration Statement on Form F-3 Filed January 13, 2023 File No. 333-269220 Dear Alexander Zwyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ron Ben-Bassat, Esq.
Show Raw Text
United States securities and exchange commission logo
January 18, 2023
Alexander Zwyer
Chief Executive Officer
NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
Re:NLS Pharmaceutics Ltd.
Registration Statement on Form F-3
Filed January 13, 2023
File No. 333-269220
Dear Alexander Zwyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ron Ben-Bassat, Esq.